Recent preliminary clinical data evidenced that, in a small cohort of post-menopausal patients diagnosed with ERα-positive breast cancer and receiving aromatase inhibitors as adjuvant hormonal therapy, a short-term estrogen depletion did not affect adiponectin serum levels. Here, CYP19A1 is linked to breast cancer.